Biogen has signed a strategic collaboration with C4 Therapeutics for the discovery and development of new therapies to treat neurological diseases, including Alzheimer's disease. The partners will explore the use of C4 Therapeutics new protein degradation platform to identify new treatments. The platform is designed to allow the discovery of molecules leveraging endogenous protein degradation mechanisms to address disease-causing proteins.C4 Therapeutics will offer targeted protein degradation expertise and research services, while Biogen will contribute through neuroscience expertise and drug development capabilities.

The companies intend to jointly research potential targets and Biogen will advance the resulting candidates into development and potential commercialization. As per the agreement, C4 Therapeutics will receive a total of up to $415 million in upfront and potential milestone payments as well as potential future royalties.